Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.51 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072920 | 0.90 | CCR1 (0.43) | CCR1C3AR1ANPEPHDAC4HDAC8 | |
| SCHEMBL4069330 | 0.86 | CCR1 (0.42) | CCR1HDAC8 | |
| SCHEMBL4064299 | 0.86 | CCR1 (0.41) | CCR1C3AR1ANPEP | |
| SCHEMBL4068388 | 0.85 | CCR1 (0.41) | CCR1C3AR1HDAC8MME | |
| SCHEMBL4072995 | 0.85 | CCR1 (0.40) | CCR1MMP8HDAC4HDAC8MMP1 | |
| SCHEMBL4072014 | 0.84 | CCR1 (0.46) | CCR1C3AR1SMN1; SMN2 | |
| SCHEMBL4060435 | 0.83 | CCR1 (0.41) | CCR1SMN1; SMN2 | |
| SCHEMBL4071304 | 0.81 | CCR1 (0.40) | CCR1 | |
| SCHEMBL2675825 | 0.80 | CCR1 (0.38) | CCR1ANPEPTSHRMMP8HDAC8 | |
| SCHEMBL2675864 | 0.80 | CCR1 (0.38) | CCR1ANPEPTSHRMMP8HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404300-B1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2009-09-30 | — | — | EP | claimed |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER INC | 2008-11-27 | — | — | US | claimed |
| US-20060204577-A1 | Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers | PFIZER PRODUCTS INC. | 2006-09-14 | — | — | US | claimed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2003000235-A9 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | claimed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | claimed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | claimed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-2961775-B1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE AND IMPROVED PROCESSABILITY | HERCULES LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10106625-B2 | Pharmaceutical compositions with enhanced performance and improved processability | HERCULES LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20160376380-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE AND IMPROVED PROCESSABILITY | HERCULES INCORPORATED (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9492550-B2 | Pharmaceutical compositions with enhanced performance and improved processability | HERCULES LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | PFIZER INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000235-A9 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | CCR1 3503/4885C3AR1 4719/4885ANPEP 1587/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | CCR1 1188/4885C3AR1 2690/4885ANPEP 217/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | CCR1 1715/4885C3AR1 707/4885ANPEP 265/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | CCR1 4570/4885C3AR1 4681/4885ANPEP 2204/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CCR1 3350/4885C3AR1 4078/4885ANPEP 2320/4885 |
| US-20060204577-A1 | Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers | PDE7A, CA6, PDE9A | CCR1 1188/4885C3AR1 2690/4885ANPEP 217/4885 |
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | ABCB11, ABCG2, LIPA | CCR1 3210/4885C3AR1 4018/4885ANPEP 2235/4885 |
| US-10106625-B2 | Pharmaceutical compositions with enhanced performance and improved processability | MCCC2, SUCLA2, HMGCR | CCR1 2206/4885C3AR1 302/4885ANPEP 3444/4885 |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | CCR1 1715/4885C3AR1 707/4885ANPEP 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.